Thereby, the methodology of integrating ctDNAs with KRAS mutation, methylation on targeted genes, and high expression level of tumor-specific proteins predominantly occupies a position in early diagnosis of pancreatic cancers. This evidence concerns the gene KRAS and familial pancreatic carcinoma.